Anti-Monkeypox virus (MPV) L1 human monoclonal neutralizing antibody (IgG1) for Therapeutics (positive control in vaccine development，benchmark in neutralizing antibodies discovery) and Diagnosis
Cat No.: GMP-MPV-Tg03-nAb001,GMP-MPV-Tg03-nAb002,GMP-MPV-Tg03-nAb003,GMP-MPV-Tg03-nAb004,GMP-MPV-Tg03-nAb005
The A33, L1, B5, and A25 genes encode the four proteins viz. A33, L1, B5, and A25, respectively. All of these immunogens are highly homologous (> 93%) between variola, monkeypox, and vaccinia. A33 is a type II integral membrane protein present as a dimer on the EV. Some evidence suggests A33 has a role in facilitating antibody-resistant cell-to-cell spread of orthopoxviruses. The A28 gene of vaccinia virus is conserved in all poxviruses and encodes a protein that is anchored to the surface of infectious intracellular mature virions (IMV) and consequently lies beneath the additional envelope of extracellular virions and required for the virus propagation. The product of the H3L gene, p35, is another envelope protein that is an immunodominant antigen found on orthopoxvirus. Strong immune responses to p35 protein have been detected in mice, sheep, rabbits, and humans. It has also been shown that the monoclonal antibodies against A28, A33, B5, L1 and H3 are cross protective cross-protective for variola, monkeypox, and vaccinia.
GeneMedi has quickly screened these neutralizing antibodies, which are valid for Monkeypox virus (MPV). They could be used as Benchmark Antibody, assist in neutralizing antibody discovery and development. They could also be used for Diagnosis. It should be noted that these antibodies have cross reactivity with vaccinia virus (VACV) and other Pox viruses.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Cat No. of Pruducts||GMP-MPV-Tg03-nAb001, GMP-MPV-Tg03-nAb002, GMP-MPV-Tg03-nAb003, GMP-MPV-Tg03-nAb004, GMP-MPV-Tg03-nAb005|
|Product Name||Anti-MPV (L1) human monoclonal neutralizing antibody (IgG1)|
|Expression platform||Mammalian (human cell)|
|Bioactivity validation||Validated in Monkeypox virus (MPV) L1 antigen protein binding affnity. ELISA validated as capture antibody and detection antibody. Pair recommendation with other L1 antibodies in L1 level test of Monkeypox virus (MPV) infectious diseases.|
|Products description||Anti-MPV (L1) human monoclonal neutralizing antibody (IgG1) is a potency validated Monkeypox virus (MPV) neutralizing antibody. It is a human IgG1 antibody produced by Mammalian (human cell). The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other L1 antibodies.|
|Purity||Purity: ≥95% (SDS-PAGE)|
|Application||This antibodies can either act as positive control in Monkeypox virus (MPV) related vaccines and neutralizing antibodies discovery and development, or act as a benchmark in Monkeypox virus (MPV) neutralization potency assay. ELISA test,Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA),immunonephelometry and POCT.|
|Formulation||Supplied as a 0.2 μM filtered solution of PBS,PH7.4.|
|Storage||Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.|